**Author(s):**

**Question:** Intraosseous compared to intravenous for Cardiac arrest

**Setting:**

**Bibliography:** . Intraosseous versus Intravenous for Cardiac arrest. Cochrane Database of Systematic Reviews [Year], Issue [Issue].

| **Certainty assessment** | | | | | | | **№ of patients** | | **Effect** | | **Certainty** | **Importance** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **№ of studies** | **Study design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Intraosseous** | **intravenous** | **Relative (95% CI)** | **Absolute (95% CI)** |
| **30-day survival** | | | | | | | | | | | | |
| 3 | randomised trials | not serious | not serious | not serious | seriousa | none | 301/4500 (6.7%) | 332/4772 (7.0%) | **RR 0.99** (0.85 to 1.15) | **1 fewer per 1,000** (from 10 fewer to 10 more) | ⨁⨁⨁◯ Moderatea | CRITICAL |
| **Return of spontaneous circulation (any)** | | | | | | | | | | | | |
| 2 | randomised trials | not serious | seriousb | not serious | seriousc | none | 1369/3762 (36.4%) | 1459/3783 (38.6%) | **OR 0.91** (0.83 to 1.00) | **22 fewer per 1,000** (from 43 fewer to 0 fewer) | ⨁⨁◯◯ Lowb,c | IMPORTANT |
| **Return of spontaneous circulation (sustained)** | | | | | | | | | | | | |
| 2 | randomised trials | not serious | seriousb | not serious | not serious | none | 860/3747 (23.0%) | 947/3771 (25.1%) | **OR 0.89** (0.80 to 0.99) | **21 fewer per 1,000** (from 40 fewer to 2 fewer) | ⨁⨁⨁◯ Moderateb | IMPORTANT |
| **Survival (30-day/ discharge) with favourable neurological outcome** | | | | | | | | | | | | |
| 3 | randomised trials | seriousd | not serious | not serious | seriousa | none | 210/4463 (4.7%) | 217/4723 (4.6%) | **OR 1.07** (0.88 to 1.30) | **3 more per 1,000** (from 5 fewer to 13 more) | ⨁⨁◯◯ Lowa,d | CRITICAL |
| **Survival at hospital discharge** | | | | | | | | | | | | |
| 3 | randomised trials | not serious | not serious | not serious | seriousa | none | 278/4483 (6.2%) | 296/4751 (6.2%) | **OR 1.04** (0.88 to 1.23) | **2 more per 1,000** (from 7 fewer to 13 more) | ⨁⨁⨁◯ Moderatea | CRITICAL |
| **Survival at 3-months** | | | | | | | | | | | | |
| 1 | randomised trials | not serious | not serious | not serious | very seriouse | none | 82/729 (11.2%) | 71/747 (9.5%) | **OR 1.21** (0.86 to 1.69) | **18 more per 1,000** (from 12 fewer to 56 more) | ⨁⨁◯◯ Lowe | CRITICAL |
| **Survival at 6-months** | | | | | | | | | | | | |
| 0 |  |  |  |  |  |  | 0/0 | 0/0 | not pooled | see comment | - | CRITICAL |
| **Survival with favourable neurological outcome at 3-months** | | | | | | | | | | | | |
| 1 | randomised trials | not serious | not serious | not serious | very seriouse | none | 75/727 (10.3%) | 67/746 (9.0%) | **OR 1.17** (0.82 to 1.65) | **14 more per 1,000** (from 15 fewer to 50 more) | ⨁⨁◯◯ Lowe | CRITICAL |
| **Survival with favourable neurological outcome at 6-months** | | | | | | | | | | | | |
| 0 |  |  |  |  |  |  | 0/0 | 0/0 | not pooled | see comment | - | CRITICAL |
| **Health-related quality of life at 3-months** | | | | | | | | | | | | |
| 1 | randomised trials | not serious | not serious | not serious | very seriouse | none | 78 | 69 | - | MD **4 higher** (2.33 lower to 10.33 higher) | ⨁⨁◯◯ Lowe | CRITICAL |
| **Health-related quality of life at 6-months** | | | | | | | | | | | | |
| 0 |  |  |  |  |  |  | 0 | 0 | - | see comment | - | CRITICAL |

**CI:** confidence interval; **MD:** mean difference; **OR:** odds ratio; **RR:** risk ratio

#### Explanations

a. Confidence interval includes both potential benefit and harm

b. Evidence of heterogeneity (I2 value>50%)

c. Confidence interval includes both no effect and potential harm

d. One trial assessed at being at high risk of bias

e. Very wide confidence that includes both potential benefit and harm